Naim Shehadeh
Overview
Explore the profile of Naim Shehadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
1338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Korutla R, Tedder D, Brogan K, Milosevic M, Wilczek M, Shehadeh N, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002672
: This study uses Sankey diagrams to analyze treatment pathways in patients with peripheral artery disease (PAD), which is a vascular condition characterized by atherosclerotic occlusion of the arteries, particularly...
2.
3.
Shehadeh N, Galassetti P, Iqbal N, Karlsson C, Monyak J, Ostridge J, et al.
J Clin Endocrinol Metab
. 2024 Oct;
PMID: 39446459
Context: The T2NOW trial of dapagliflozin or saxagliptin versus placebo in pediatric patients with type 2 diabetes (T2D) demonstrated promising efficacy data for dapagliflozin and did not raise any safety...
4.
Ayada G, Zolotov S, Cohen R, Lavi T, Abdul-Ghani M, Shehadeh N, et al.
Diabetes Technol Ther
. 2024 Oct;
27(2):144-146.
PMID: 39360432
No abstract available.
5.
Nakhleh A, Shehadeh N, Mansour B
Pituitary
. 2024 Sep;
27(5):731-736.
PMID: 39240512
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have diverse effects on sodium and water homeostasis. They decrease thirst perception, potentially inhibit arginine vasopressin (AVP) production, and induce natriuresis. We present...
6.
Nakhleh A, Halfin E, Shehadeh N
World J Diabetes
. 2024 Aug;
15(7):1384-1389.
PMID: 39099816
The surge in type 2 diabetes mellitus (T2DM) is tightly linked to obesity, leading to ectopic fat accumulation in internal organs. Weight management has become a cornerstone of T2DM treatment,...
7.
Nakhleh A, Abdul-Ghani M, Gazit S, Gross A, Livnat I, Greenbloom M, et al.
Diabetes Obes Metab
. 2024 Apr;
26(8):3058-3067.
PMID: 38680053
Aim: To examine the renal effects of sodium-glucose cotransporter-2 (SGLT2) inhibition among non-diabetic individuals with chronic kidney disease (CKD) in a real-world setting. Methods: We collected de-identified data on adults...
8.
Nakhleh A, Mazareeb J, Darawshi S, Masri A, Shehadeh N
Clin Med Insights Endocrinol Diabetes
. 2024 Mar;
17:11795514241238058.
PMID: 38495948
This review evaluates the current evidence on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan. All studies...
9.
Shehadeh N, Barrett T, Galassetti P, Karlsson C, Monyak J, Iqbal N, et al.
NEJM Evid
. 2024 Feb;
2(12):EVIDoa2300210.
PMID: 38320500
BACKGROUND: Incidence of type 2 diabetes (T2D) in children and adolescents is increasing, but treatment options are limited. METHODS: This was a 26-week, phase 3 trial with a 26-week extension...
10.
Nakhleh A, Othman A, Masri A, Zloczower M, Zolotov S, Shehadeh N
Biomedicines
. 2023 Oct;
11(10).
PMID: 37893063
Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. Methods: A retrospective...